Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.

Cancer treatment reviews - 1 Apr 2023

Martinelli Erika, Arnold Dirk, Cervantes Andres, Stintzing Sebastian, Van Cutsem Eric, Tabernero Josep, Taieb Julien, Wasan Harpreet, Ciardiello Fortunato

Abstract excerpt

Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in approximately 8-12% of patients and is characterised by an aggressive clinical course and poor prognosis. Here we review the current knowledge on BRAFV600E-mutant mCRC and provide a series of consensus statements on its clinical management. The treatment landscape for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Rectal Neoplasms

Source

Identifiers

PMID: 36931147
DOI: 10.1016/j.ctrv.2023.102541

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.PMID 36931147Read ↗

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities.Semantic proximity Read ↗

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Semantic proximity Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Semantic proximity Read ↗

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.Semantic proximity Read ↗

The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.Semantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.Semantic proximity Read ↗

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.